BTIG Research Reaffirms “Buy” Rating for NRx Pharmaceuticals (NASDAQ:NRXP)

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating reiterated by equities research analysts at BTIG Research in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $25.00 price objective on the stock.

A number of other research firms have also recently weighed in on NRXP. Zacks Research cut shares of NRx Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Monday, January 26th. Weiss Ratings restated a “sell (e+)” rating on shares of NRx Pharmaceuticals in a research report on Monday, December 29th. Ascendiant Capital Markets reaffirmed a “buy” rating and set a $48.00 price target (up previously from $47.00) on shares of NRx Pharmaceuticals in a report on Friday, January 2nd. Wall Street Zen raised NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, November 23rd. Finally, HC Wainwright restated a “buy” rating on shares of NRx Pharmaceuticals in a research report on Wednesday, January 21st. Four analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat, NRx Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $36.75.

NRx Pharmaceuticals Price Performance

Shares of NASDAQ NRXP traded up $0.05 during mid-day trading on Wednesday, hitting $1.85. The company had a trading volume of 179,376 shares, compared to its average volume of 1,304,563. NRx Pharmaceuticals has a 12 month low of $1.58 and a 12 month high of $3.84. The stock has a market cap of $54.61 million, a price-to-earnings ratio of -0.79 and a beta of 1.91. The firm’s 50 day simple moving average is $2.20 and its two-hundred day simple moving average is $2.56.

Institutional Investors Weigh In On NRx Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of NRXP. Ethos Financial Group LLC acquired a new position in NRx Pharmaceuticals in the 3rd quarter valued at approximately $39,000. Sjbenen Advisory LLC acquired a new position in shares of NRx Pharmaceuticals in the fourth quarter worth $41,000. One Wealth Management Investment & Advisory Services LLC raised its holdings in shares of NRx Pharmaceuticals by 86.1% during the third quarter. One Wealth Management Investment & Advisory Services LLC now owns 27,991 shares of the company’s stock worth $92,000 after acquiring an additional 12,950 shares in the last quarter. Global Retirement Partners LLC purchased a new stake in shares of NRx Pharmaceuticals during the fourth quarter worth $107,000. Finally, Two Sigma Investments LP boosted its position in NRx Pharmaceuticals by 66.4% during the third quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock valued at $173,000 after purchasing an additional 20,880 shares during the last quarter. Institutional investors and hedge funds own 4.27% of the company’s stock.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.